Q3 2025 Journey Medical Corp Earnings Call Transcript
Key Points
- Journey Medical Corp (DERM) reported a 21% year-over-year revenue growth for the third quarter of 2025.
- Emrosi, the company's oral treatment for rosacea, contributed $4.9 million to the top line, marking a 75% increase compared to Q2.
- The company achieved a positive adjusted EBITDA of $1.7 million for Q3 2025, compared to $300,000 in the same period last year.
- Emrosi's prescription growth was approximately 146% in Q3, with 18,198 prescriptions compared to 7,394 in Q2.
- Over 100 million of the 187 million commercial lives currently have access to Emrosi, with successful contracts with two of the three largest GPOs.
- Revenue for legacy and core products declined 16% year-over-year, mainly due to generic competition for Accutane.
- Gross margin decreased to 67.4% in Q3 2025 from 69.4% in the same period last year.
- The company reported a GAAP net loss of $2.3 million for the third quarter of 2025.
- The reliance on the patient co-pay assistance program remains high as downstream health plan formulary adoption takes time.
- Accutane faces ongoing challenges from generic competition, impacting its revenue stability.
Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to Journey Medical's third quarter 2025 financial results and corporate update conference call.
(Operator Instructions)
Participants of this call are advised that the audio of this call is being broadcast live over the Internet and is also being recorded for playback purposes. A webcast replay of this call will be available approximately one hour after the call for approximately 30 days.
I would now like to turn the call over to Ms. Jaclyn Jaffe, the company's Senior Director of Corporate Operations. Please go ahead, Jaclyn.
Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer; and Joseph Benesch, Chief Financial Officer. Joining for the Q&A portion of the call will be Ramsey Alloush, Chief Operating Officer and General Counsel.
During this call,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
